Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI; Tsu-Yi Chao; T. Chao; C. Chiu; Y. Lu; H. Shiah; Y. Wu; G. Gerald Fetterly; N. Hung; D.L. Cutler; R. Kwan; D. Douglas Kramer; W. Chan; T. Hung

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI, Tsu-Yi Chao, T. Chao, C. Chiu, Y. Lu, H. Shiah, Y. Wu, G. Gerald Fetterly, N. Hung, D.L. Cutler, R. Kwan, D. Douglas Kramer, W. Chan, T. Hung

研究成果: 雜誌貢獻 › 文章 › 同行評審

摘要

Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

原文	英語
期刊	Annals of Oncology
出版狀態	已發佈 - 10月 21 2018

UN SDG

此研究成果有助於以下永續發展目標

存取文件

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients

引用此

DAI, M., Chao, T-Y., Chao, T., Chiu, C., Lu, Y., Shiah, H., Wu, Y., Gerald Fetterly, G., Hung, N., Cutler, D. L., Kwan, R., Douglas Kramer, D., Chan, W., & Hung, T. (2018). Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. Annals of Oncology. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients

DAI, M, Chao, T-Y, Chao, T, Chiu, C, Lu, Y, Shiah, H, Wu, Y, Gerald Fetterly, G, Hung, N, Cutler, DL, Kwan, R, Douglas Kramer, D, Chan, W & Hung, T 2018, 'Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients', Annals of Oncology. <https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients>

@article{c37e951a06c9408f9c3697e058b3a3b8,

title = "Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients",

abstract = "Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.",

author = "M. DAI and Tsu-Yi Chao and T. Chao and C. Chiu and Y. Lu and H. Shiah and Y. Wu and {Gerald Fetterly}, G. and N. Hung and D.L. Cutler and R. Kwan and {Douglas Kramer}, D. and W. Chan and T. Hung",

year = "2018",

month = oct,

day = "21",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

AU - DAI, M.

AU - Chao, Tsu-Yi

AU - Chao, T.

AU - Chiu, C.

AU - Lu, Y.

AU - Shiah, H.

AU - Wu, Y.

AU - Gerald Fetterly, G.

AU - Hung, N.

AU - Cutler, D.L.

AU - Kwan, R.

AU - Douglas Kramer, D.

AU - Chan, W.

AU - Hung, T.

PY - 2018/10/21

Y1 - 2018/10/21

N2 - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

AB - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

M3 - Article

SN - 0923-7534

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

摘要

UN SDG

存取文件

指紋

引用此